Genetic and Genomic Factors in Prostate Cancer for American Men
Official title: Genetic and Genomic Variation in Prostate Cancer
Funded at Dana-Farber Cancer Inst · NIH-11535329 · Data updated 2026-11-12
This project studies how inherited genes and tumor genetics influence how often prostate cancer occurs and how it behaves in American men.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 7, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $56,012 |
| NIH project number | 3R01CA259200-05S6 |
| Project ID | NIH-11535329 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adult men diagnosed with prostate cancer or at high risk due to family history or genetic factors, with diverse ancestry represented.
✕Less likely to help
Individuals without prostate cancer or related genetic risk factors may not directly benefit.
What this research studies
If you have or are at risk for prostate cancer, this project will look at many genetic differences that people inherit and how tumor genetics vary between individuals. Researchers will analyze germline and tumor DNA to understand why prostate cancer develops and how it might progress or respond to treatment. The study emphasizes diverse populations to ensure findings apply broadly, including men of African descent. Results could inform personalized risk assessment and future tailored therapies. The work will use existing samples and data to map which genetic variants are most associated with prostate cancer in real-world patients.
Why it matters
Potential benefit: Better understanding of genetic risk and tumor biology could lead to more accurate risk prediction and personalized treatment options for prostate cancer.
How similar studies have gone: Previous studies have linked germline variants and somatic mutations to prostate cancer risk and progression, with ongoing work refining these associations.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Rebbeck, Timothy Richard — Dana-Farber Cancer Inst
- Study coordinator: Rebbeck, Timothy Richard
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.